Literature DB >> 21763962

New insights into the biology of renal cell carcinoma.

Lianjie Li1, William G Kaelin.   

Abstract

Ninety percent or more of kidney cancers are believed to be of epithelial cell origin, and are referred to as renal cell carcinoma (RCC), which are further subdivided based on histology into clear-cell RCC (75%), papillary RCC (15%), chromophobe tumor (5%), and oncocytoma (5%). Some genes confer an increased risk of these various histologic RCC subtypes. In practice, there is some overlap among the histologic subtypes, and there are some shared molecular features among these tumor types. This review focuses primarily on the most common form of RCC, clear-cell renal carcinoma, noting some recent advances in the other histologic subtypes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763962      PMCID: PMC3161447          DOI: 10.1016/j.hoc.2011.04.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  156 in total

1.  The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Authors:  S Koochekpour; M Jeffers; P H Wang; C Gong; G A Taylor; L M Roessler; R Stearman; J R Vasselli; W G Stetler-Stevenson; W G Kaelin; W M Linehan; R D Klausner; J R Gnarra; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.

Authors:  Jun Yang; Adrian M Jubb; Luke Pike; Francesca M Buffa; Helen Turley; Dilair Baban; Russell Leek; Kevin C Gatter; Jiannis Ragoussis; Adrian L Harris
Journal:  Cancer Res       Date:  2010-08-03       Impact factor: 12.701

3.  Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility.

Authors:  Tien Hsu; Yair Adereth; Nurgun Kose; Vincent Dammai
Journal:  J Biol Chem       Date:  2006-02-27       Impact factor: 5.157

4.  Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis.

Authors:  R H Giles; M P Lolkema; C M Snijckers; M Belderbos; P van der Groep; D A Mans; M van Beest; M van Noort; R Goldschmeding; P J van Diest; H Clevers; E E Voest
Journal:  Oncogene       Date:  2006-05-18       Impact factor: 9.867

5.  Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.

Authors:  Noboru Nakaigawa; Masahiro Yao; Masaya Baba; Shingo Kato; Takeshi Kishida; Keiko Hattori; Yoji Nagashima; Yoshinobu Kubota
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

6.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

Authors:  Gabriele Bergers; Steven Song; Nicole Meyer-Morse; Emily Bergsland; Douglas Hanahan
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

Authors:  O Iliopoulos; A P Levy; C Jiang; W G Kaelin; M A Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

8.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

9.  Regulation of endocytosis via the oxygen-sensing pathway.

Authors:  Yi Wang; Olga Roche; Mathew S Yan; Greg Finak; Andrew J Evans; Julie L Metcalf; Bridgid E Hast; Sara C Hanna; Bill Wondergem; Kyle A Furge; Meredith S Irwin; William Y Kim; Bin T Teh; Sergio Grinstein; Morag Park; Philip A Marsden; Michael Ohh
Journal:  Nat Med       Date:  2009-03-01       Impact factor: 53.440

10.  O2 regulates stem cells through Wnt/β-catenin signalling.

Authors:  Jolly Mazumdar; W Timothy O'Brien; Randall S Johnson; Joseph C LaManna; Juan C Chavez; Peter S Klein; M Celeste Simon
Journal:  Nat Cell Biol       Date:  2010-09-19       Impact factor: 28.824

View more
  35 in total

1.  An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors.

Authors:  Jerzy O Szablowski; Jevgenij A Raskatov; Peter B Dervan
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

2.  Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications.

Authors:  Shahzeena Aslam; Tim Eisen
Journal:  Ther Adv Med Oncol       Date:  2013-11       Impact factor: 8.168

3.  Cilia and cilia-associated proteins in cancer.

Authors:  Tamina Seeger-Nukpezah; Joy L Little; Victoria Serzhanova; Erica A Golemis
Journal:  Drug Discov Today Dis Mech       Date:  2013-12-01

Review 4.  Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

Authors:  Luís León; Roberto García-Figueiras; Roberto García-Figueras; Cristina Suárez; Antonia Arjonilla; Javier Puente; Blanca Vargas; Maria José Méndez Vidal; Carmen Sebastiá
Journal:  Target Oncol       Date:  2013-12-12       Impact factor: 4.493

5.  RNF20 Suppresses Tumorigenesis by Inhibiting the SREBP1c-PTTG1 Axis in Kidney Cancer.

Authors:  Jae Ho Lee; Yong Geun Jeon; Kyoung-Hwa Lee; Hye Won Lee; Jeu Park; Hagoon Jang; Minyong Kang; Hye Sun Lee; Hee Jin Cho; Do-Hyun Nam; Cheol Kwak; Jae Bum Kim
Journal:  Mol Cell Biol       Date:  2017-10-27       Impact factor: 4.272

6.  The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Authors:  Toni K Choueiri; André P Fay; Robert Gagnon; Ying Lin; Brittany Bahamon; Victoria Brown; Jonathan E Rosenberg; Thomas E Hutson; Katherine L Baker-Neblett; Christopher Carpenter; Yuan Liu; Lini Pandite; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

Review 7.  Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.

Authors:  Denis Migliorini; Sven Haller; Doron Merkler; Angela Pugliesi-Rinaldi; Avinash Koka; Karl Schaller; Beatrice Leemann; Pierre-Yves Dietrich
Journal:  CNS Oncol       Date:  2015-10-26

Review 8.  Metabolism of kidney cancer: from the lab to clinical practice.

Authors:  Sunil Sudarshan; Jose A Karam; James Brugarolas; R Houston Thompson; Robert Uzzo; Brian Rini; Vitaly Margulis; Jean-Jacques Patard; Bernard Escudier; W Marston Linehan
Journal:  Eur Urol       Date:  2012-09-28       Impact factor: 20.096

9.  β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.

Authors:  Ruhee Dere; Ashley Lyn Perkins; Tasneem Bawa-Khalfe; Darius Jonasch; Cheryl Lyn Walker
Journal:  J Am Soc Nephrol       Date:  2014-10-13       Impact factor: 10.121

10.  Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.

Authors:  Fabio A B Schutz; Mark M Pomerantz; Kathryn P Gray; Michael B Atkins; Jonathan E Rosenberg; Michelle S Hirsch; David F McDermott; Megan E Lampron; Gwo-Shu Mary Lee; Sabina Signoretti; Philip W Kantoff; Matthew L Freedman; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2012-12-07       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.